Literature DB >> 29621372

Outcomes From Lateral Eyelid Coupling for Facial Paralysis Using the Modified Tarsoconjunctival Flap.

Raj Dedhia1, Tsung-Yen Hsieh1, Oliver Chin1, Taha Z Shipchandler2, Travis T Tollefson1.   

Abstract

IMPORTANCE: In the setting of facial paralysis, inadequate eyelid closure and lower eyelid ectropion can lead to corneal exposure and impaired quality of life. Repair of paralytic ectropion is challenging, and an ideal surgical approach for all cases has not been identified.
OBJECTIVE: To assess the patient-reported outcomes and eyelid position improvement in patients with flaccid facial paralysis undergoing lateral eyelid coupling with a tarsal strip canthoplasty and modified tarsoconjunctival flap to correct eyelid malposition. DESIGN, SETTING, AND PARTICIPANTS: Review of medical records of adults with flaccid facial paralysis who underwent a single-stage tarsal strip canthoplasty and modified tarsoconjunctival flap at a tertiary academic center. Inclusion criteria included a minimum of 3 months of follow-up. INTERVENTION: The lateral upper and lower eyelid are coupled with the hybrid tarsoconjunctival flap. MAIN OUTCOMES AND MEASURES: Patient-reported outcome measures and objective photograph analysis. Preoperative and postoperative Facial Clinimetric Evaluation (FaCE) scores and Moe Ectropion Grading Scale scores were compared. The relationship between radiation therapy (RT) and outcomes was analyzed.
RESULTS: Sixteen patients (8 [50%] female; mean [SD] age at surgery, 71.5 [9.6] years) were identified between January 2014 and August 2017. Twelve (75%) had paralysis from facial nerve sacrifice during cancer ablation. The mean time between paralysis and referral for surgical repair of ectropion was 23 months (range, 0-151 months) and mean follow-up after surgery was 9.8 months (range, 3-39 months). The most common symptom was epiphora, which was significantly reduced after surgery (75% vs 25%; P = .01). Median Moe Ectropion Grading Scale score improved from 3 (interquartile range, 2-3) to 0 (interquartile range, 0-1; P < .001). Quality of life measured using the FaCE scale demonstrated a significant improvement in mean eye comfort (from 18.8 [95% CI, 2.3-35.2] to 47.9 [95% CI, 31.9-63.9]; P = .01) and lacrimal control scores (from 12.5 [95% CI, 0-29.2] to 45.8 [95% CI, 29.3-62.3]; P = .03) in the 6 patients in the RT group, but no difference in the 4 patients in the non-RT group. CONCLUSIONS AND RELEVANCE: Ocular symptoms, eyelid appearance, and quality of life were improved after lateral eyelid coupling among patients with flaccid facial paralysis and paralytic ectropion. The tarsoconjunctival flap does limit peripheral vision, but is reversible if dynamic eyelid closure is returned with nerve grafting. LEVEL OF EVIDENCE: 4.

Entities:  

Mesh:

Year:  2018        PMID: 29621372      PMCID: PMC6233623          DOI: 10.1001/jamafacial.2018.0070

Source DB:  PubMed          Journal:  JAMA Facial Plast Surg        ISSN: 2168-6076            Impact factor:   4.611


  18 in total

1.  Survey: management of paralytic lagophthalmos and paralytic ectropion.

Authors:  S M Tucker; P M Santos
Journal:  Otolaryngol Head Neck Surg       Date:  1999-06       Impact factor: 3.497

Review 2.  Surgical tips on the lateral tarsal strip.

Authors:  J M Olver
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

Review 3.  Ectropion.

Authors:  Eliana Guimaraes de Menezes Bedran; Maria Valéria Correia Pereira; Taliana Freitas Bernardes
Journal:  Semin Ophthalmol       Date:  2010-05       Impact factor: 1.975

4.  Eyelid movements in facial paralysis.

Authors:  P A Sibony; C Evinger; K A Manning
Journal:  Arch Ophthalmol       Date:  1991-11

5.  A useful augmented lateral tarsal strip tarsorrhaphy for paralytic ectropion.

Authors:  Lydia Chang; Jane Olver
Journal:  Ophthalmology       Date:  2005-12-15       Impact factor: 12.079

6.  Single-stage repair of paralytic ectropion using a novel modification of the tarsoconjunctival flap.

Authors:  Ahmed S Sufyan; H B Harold Lee; Hassan Shah; William R Nunery; Mimi S Kokoska; Taha Z Shipchandler
Journal:  JAMA Facial Plast Surg       Date:  2014 Mar-Apr       Impact factor: 4.611

7.  Transposed Corrugator Supercilii Muscle-Tendon Unit Flap for Contralateral Paralytic Medial Ectropion Repair.

Authors:  Dane J Genther; Leslie R Kim; Myriam D Loyo; Kofi D Boahene
Journal:  JAMA Facial Plast Surg       Date:  2016-05-01       Impact factor: 4.611

8.  Lateral tarsoconjunctival onlay flap lower eyelid suspension in facial nerve paresis.

Authors:  Jeremiah P Tao; Swapna Vemuri; Amy D Patel; Chris Compton; William R Nunery
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2014 Jul-Aug       Impact factor: 1.746

9.  The lateral transorbital canthopexy for correction and prevention of ectropion: report of a procedure, grading system, and outcome study.

Authors:  K S Moe; T Linder
Journal:  Arch Facial Plast Surg       Date:  2000 Jan-Mar

10.  The minimally invasive, orbicularis-sparing, lower eyelid recession for mild to moderate lower eyelid retraction with reduced orbicularis strength.

Authors:  Donald B Yoo; Garrett R Griffin; Babak Azizzadeh; Guy G Massry
Journal:  JAMA Facial Plast Surg       Date:  2014 Mar-Apr       Impact factor: 4.611

View more
  3 in total

Review 1.  Eyelid Malposition Repair: A Review of the Literature and Current Techniques.

Authors:  Ashley J Guthrie; Pooja Kadakia; Joshua Rosenberg
Journal:  Semin Plast Surg       Date:  2019-04-26       Impact factor: 2.314

2.  The efficacy and safety of cupping therapy for treating of intractable peripheral facial paralysis: A protocol for systematic review and meta-analysis.

Authors:  Zhiwen Cao; Lin Jiao; Hongyu Wang; Jun Li; Genping Zhong; Daocheng Zhu; Wei Xu; MengKe Jin
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

3.  Electroacupuncture combined with Qianzhengsan decoction for the treatment of peripheral facial paralysis: A retrospective study.

Authors:  Wei-Qiang Chen; Qiang Li
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.